These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 15991889)

  • 1. Respirable antisense oligonucleotides as novel therapeutic agents for asthma and other pulmonary diseases.
    Nyce JW
    Expert Opin Investig Drugs; 1997 Sep; 6(9):1149-56. PubMed ID: 15991889
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Respirable antisense oligonucleotides: a new drug class for respiratory disease.
    Tanaka M; Nyce JW
    Respir Res; 2001; 2(1):5-9. PubMed ID: 11686859
    [TBL] [Abstract][Full Text] [Related]  

  • 3. RASONs: a novel antisense oligonucleotide therapeutic approach for asthma.
    Sandrasagra A; Tang L; Leonard SA; Teng K; Li Y; Mannion JC; Nyce JW
    Expert Opin Biol Ther; 2001 Nov; 1(6):979-83. PubMed ID: 11728229
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Respirable antisense oligonucleotides: a new, third drug class targeting respiratory disease.
    Nyce J
    Curr Opin Allergy Clin Immunol; 2002 Dec; 2(6):533-6. PubMed ID: 14752337
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Respirable antisense oligonucleotide (RASON) therapy for allergic asthma.
    Metzger WJ; Nyce JW
    BioDrugs; 1999 Oct; 12(4):237-43. PubMed ID: 18031178
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery and development of respirable antisense therapeutics for asthma.
    Sandrasagra A; Leonard SA; Tang L; Teng K; Li Y; Ball HA; Mannion JC; Nyce JW
    Antisense Nucleic Acid Drug Dev; 2002 Jun; 12(3):177-81. PubMed ID: 12162700
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical potential of respirable antisense oligonucleotides (RASONs) in asthma.
    Ball HA; Sandrasagra A; Tang L; Van Scott M; Wild J; Nyce JW
    Am J Pharmacogenomics; 2003; 3(2):97-106. PubMed ID: 12749727
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Absorption, distribution, metabolism, and excretion of a respirable antisense oligonucleotide for asthma.
    Ali S; Leonard SA; Kukoly CA; Metzger WJ; Wooles WR; McGinty JF; Tanaka M; Sandrasagra A; Nyce JW
    Am J Respir Crit Care Med; 2001 Mar; 163(4):989-93. PubMed ID: 11282778
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oligonucleotide Therapy for Obstructive and Restrictive Respiratory Diseases.
    Liao W; Dong J; Peh HY; Tan LH; Lim KS; Li L; Wong WF
    Molecules; 2017 Jan; 22(1):. PubMed ID: 28106744
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An RNA external guide sequence ribozyme targeting human interleukin-4 receptor alpha mRNA.
    Dreyfus DH; Matczuk A; Fuleihan R
    Int Immunopharmacol; 2004 Aug; 4(8):1015-27. PubMed ID: 15222976
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oligonucleotides: New therapeutic approaches for asthma and chronic obstructive pulmonary disease.
    Parry-Billings M; Ferrari N; Seguin R
    Curr Opin Investig Drugs; 2010 Nov; 11(11):1276-85. PubMed ID: 21157647
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antisense oligonucleotides as therapeutics for malignant diseases.
    Ho PT; Parkinson DR
    Semin Oncol; 1997 Apr; 24(2):187-202. PubMed ID: 9129689
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Local administration of antisense phosphorothioate oligonucleotides to the c-kit ligand, stem cell factor, suppresses airway inflammation and IL-4 production in a murine model of asthma.
    Finotto S; Buerke M; Lingnau K; Schmitt E; Galle PR; Neurath MF
    J Allergy Clin Immunol; 2001 Feb; 107(2):279-86. PubMed ID: 11174194
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Local and systemic tolerability of a 2'O-methoxyethyl antisense oligonucleotide targeting interleukin-4 receptor-α delivery by inhalation in mouse and monkey.
    Fey RA; Templin MV; McDonald JD; Yu RZ; Hutt JA; Gigliotti AP; Henry SP; Reed MD
    Inhal Toxicol; 2014 Jul; 26(8):452-63. PubMed ID: 24932560
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of allergic airway inflammation and hyperresponsiveness by antisense-induced local blockade of GATA-3 expression.
    Finotto S; De Sanctis GT; Lehr HA; Herz U; Buerke M; Schipp M; Bartsch B; Atreya R; Schmitt E; Galle PR; Renz H; Neurath MF
    J Exp Med; 2001 Jun; 193(11):1247-60. PubMed ID: 11390432
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Liver as a target for oligonucleotide therapeutics.
    Sehgal A; Vaishnaw A; Fitzgerald K
    J Hepatol; 2013 Dec; 59(6):1354-9. PubMed ID: 23770039
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antisense therapy for angioplasty restenosis. Some critical considerations.
    Bennett MR; Schwartz SM
    Circulation; 1995 Oct; 92(7):1981-93. PubMed ID: 7671381
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A review of antisense therapeutic interventions for molecular biological targets in asthma.
    Popescu FD; Popescu F
    Biologics; 2007 Sep; 1(3):271-83. PubMed ID: 19707336
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Oligonucleotide therapeutics - an emerging novel class of compounds].
    Wacheck V
    Wien Med Wochenschr; 2006 Sep; 156(17-18):481-7. PubMed ID: 17041803
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Advantageous toxicity profile of inhaled antisense oligonucleotides following chronic dosing in non-human primates.
    Guimond A; Viau E; Aubé P; Renzi PM; Paquet L; Ferrari N
    Pulm Pharmacol Ther; 2008 Dec; 21(6):845-54. PubMed ID: 18761414
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.